On September 30, INSILICO rose 5.96% in regular trading, trading at 58.95 HKD/share, with turnover of approximately HKD 221 million. The stock has gained steadily over recent sessions as the market continues to digest a significant AI collaboration announcement.
On the news front, the company recently announced a joint development partnership with a frontier foundation model laboratory, with a contract value of up to tens of millions of U.S. dollars. Under the agreement, both parties will leverage INSILICO's proprietary MMAI Gym training framework to co-develop, validate, and commercialize a suite of frontier foundation models specifically designed for biological research. INSILICO will contribute proprietary datasets spanning multiple life science tasks and conduct closed-loop wet-lab validation on model outputs during training. The partnership also establishes a revenue-sharing model to drive global commercialization through both parties' biopharma networks.
The deal has attracted sustained market attention since its disclosure on September 21, with the stock already responding positively in prior sessions. Major brokerages including JPMorgan and Citi maintain bullish ratings on INSILICO, with target prices of HKD 71 and HKD 85 respectively, citing the company's leading position in AI-driven drug discovery and continued commercial value realization.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments